Alexandria Venture Investments has contributed to the debut round for newly launched protein therapeutics startup Stablix Therapeutics.

US-based protein stabilisation technology developer Stablix Therapeutics launched yesterday with $63m in series A funding from investors including life science real estate investment trust Alexandria Real Estate Equities.

The round was led by venture capital firm Versant Ventures and included New Enterprise Associates, Cormorant Capital and Euclidean Capital while Alexandria Real Estate Equities took part through its Alexandria Venture Investments unit.

Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn